Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD

• Published in: Gut Vol. 71; no. 9; pp. 1926 - 1928
• Main Authors: Cannatelli, Rosanna, Ferretti, Francesca, Carmagnola, Stefania, Bergna, Irene Maria Bambina, Monico, Maria Camilla, Maconi, Giovanni, Ardizzone, Sandro
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01.09.2022; BMJ Publishing Group LTD
• Subjects: adverse drug reactions; Azathioprine; Coronaviruses; COVID-19; COVID-19 vaccines; Crohns disease; Demographics; Drug dosages; Immunization; Inflammatory bowel disease; Inflammatory diseases; Multivariate analysis; Patients; Population; PostScript; Remission (Medicine); Risk factors; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; Vaccination
• ISSN: 0017-5749; 1468-3288
• DOI: 10.1136/gutjnl-2021-326237

According to univariate and multivariate analyses (online supplemental file 1) and in line with a recent survey by Botwin et al,7 AEs are more common among younger patients (OR 0.96, p<0.0005) and in cases of previous COVID-19 infection (OR 2.3, p=0.021). Regarding ongoing therapy, we found azathioprine (OR 0.39) to be inversely correlated to the presence of any AEs, while anti-tumour necrosis factor therapy (OR 2.01) was statistically significant only in the univariate analysis. [...]in the multivariate analysis, female gender was found to be a risk factor for developing any AEs (OR 1.96). [...]our data were based on a short-term follow-up and further studies on long-term AEs with objective markers are needed to state clearer recommendations.